B O O K - American College of Rheumatology

ACR Poster Session A
383. Efficacy and Safety of Ocrelizumab in Patients with Active
Rheumatoid Arthritis Who Had an Inadequate Response to
Methotrexate: Results from the Phase III STAGE Trial. William
F. C. Rigby 2 , Hans Peter T. Tony 7 , Kurt R. Oelke 5 , Bernard G.
Combe 8 , Andrew J. Laster 1 , Helen Travers 6 , Carlos A. Von
Muhlen 4 , Elena Fisheleva 6 , Carmen Martin 6 and Wolfgang
Dummer 3 , 1 Arthritis & Osteoporosis Consultants of the
Carolinas, Charlotte, NC, 2 Dartmouth Medical School, Lebanon,
NH, 3 Genentech Inc, San Francisco, CA, 4 Pontifical Catholic
University of Rio Grande do Sul, Porto Alegre, Brazil, 5 Rheumatic
Disease Center, Glendale, WI, 6 Roche, Welwyn Garden City,
UK, 7 Universitätsklinikum Würzburg, Wuerzburg, Germany,
8
Université Montpellier, Montpellier, France.
384. First Experiences with Pregnancies in RA Patients (pts)
Receiving Tocilizumab (TCZ) Therapy. Andrea Rubbert-Roth 4 ,
Philippe M. Goupille 1 , Shahrzad Moosavi 3 and Antony Hou 2 ,
1
Hopital Trousseau, Tours, France, 2 Inland Rheumatology Clinical
Trials, Upland, CA, 3 Roche, Nutley, NJ, 4 University of Cologne,
Cologne, Germany.
385. Golimumab and Cardiovascular Disease Markers in
Inflammatory Arthritides. Bruce Kirkham 3 , Mary C. Wasko 8 ,
Joan M. Bathon 4 , Elizabeth C. Hsia 2 , Roy M. Fleischmann 6 , Mark
C. Genovese 7 , Eric L. Matteson 5 , Hongjuan Liu 1 and Mahboob U.
Rahman 2 , 1 Centocor Research and Development, Inc., 2 Centocor
Research and Development, Inc./Univ. of Pennsylvania School
of Medicine, Malvern, PA, 3 Guy’s and St. Thomas’ Hospital,
London, United Kingdom, 4 Johns Hopkins Univ., School of
Medicine, Baltimore, MD, 5 Mayo Clinic, Rochester, MN,
6
Rheumatology Associates, Dallas, TX, 7 Stanford University,
Sunnyvale, CA, 8 Univ. of Pittsburgh.
386. Golimumab and Cardiovascular Disease: Carotid Artery
Ultrasound Evaluation and Cardiovascular Adverse Events.
Joan M. Bathon 5 , Mary Chester Wasko 7 , Bruce Kirkham 4 , Pierre-
Jean Touboul 6 , Elizabeth C. Hsia 3 , Weichun Xu 2 , Jiandong Lu 1 and
Mahboob U. Rahman 3 , 1 Centocor Research and Development,
Inc., Malvern, PA, 2 Centocor Research and Development,
Inc., 3 Centocor Research and Development, Inc./Univ. of
Pennsylvania School of Medicine, Malvern, PA, 4 Guy’s & St.
Thomas’ Hospital, London, United Kingdom, 5 Johns Hopkins
University, Baltimore, MD, 6 Paris-Diderot University, London,
United Kingdom, 7 University of Pittsburgh, Pittsburgh, PA.
387. Hepatitis B Virus Reactivation in Rheumatoid Arthritis and
Ankylosing Spondylitis Patients Using Anti-TNFα Agents: A
Retrospective Analysis of 52 Cases with or without Anti-Viral
Prophylaxis. Han Hee Ryu 5 , Eun Young Lee 5 , Kichul Shin 4 , In
Ah Choi 5 , Chul Kim 5 , Yoon Jong Lee 5 , Bin Yoo 7 , Min-Chan Park 6 ,
Yong-Beom Park 6 , Sang-Cheol Bae 1 , Wan Hee Yoo 3 , Sung Il
Kim 2 , Jun Wan Kim 5 , Eun Bong Lee 5 and Yeong Wook Song 5 ,
1
Department of Rheumatology, Hanyang University Hospital for
Rheumatic Diseases, Seoul, Korea, 2 Division of Rheumatology,
Department of Internal Medicine Pusan National University
Hospital Institutes, Busan, Korea, 3 Division of Rheumatology,
Department of Internal Medicine, Chonbuk National University
Medical School and Research Institute of Clinical Medicine,
Jeonju, Korea, 4 Division of Rheumatology, Department of
Internal Medicine, Seoul National University Hospital, Seoul,
Korea, Republic of, 5 Division of Rheumatology, Department of
Internal Medicine, Seoul National University Hospital, Seoul,
Korea, 6 Divsion of Rheumatology, Department of Internal
Medicine, Yonsei University College of Medicine, Seoul, Korea,
7
Divsion or Rheumatology, Department of Internal Medicine,
University of Ulsan, Asan Medical Center, Seoul, Korea.
388. Individual Dose Response Relation for MTX: Prediction of the
Optimally Effective Dose in Patients with Early Rheumatoid
Arthritis. Paco M. J. Welsing 1 , Marije F. Bakker 2 and Johannes
W. G. Jacobs 2 , 1 Rheumatology & Clinical Immunology and
Julius Center for Health Sciences and Primary Care, University
Medical Center Utrecht, The Netherlands, 2 Rheumatology &
Clinical Immunology, University Medical Center Utrecht, The
Netherlands.
389. Long-Term Effect of Anti TNF-Alpha Therapies on Insulin
Resistance, Body Composition and Adipokines in Rheumatoid
Arthritis Patients. Esmeralda Delgado-Frias 3 , Vanesa Hernández-
Hernández 2 , Iván Ferraz-Amaro 1 , Juan Carlos Quevedo 1 , Jose R.
Muñiz, Maria T. Arce-Franco, Judith Lopez-Fernandez, Andres
Franco-Maside and Federico Diaz-Gonzalez, 1 La Laguna, S/C
Tenerife, Spain, 2 La Laguna, S/C Tenerfe, Spain, 3 Hospital
Universitario de Canarias, Tenerife, La Laguna, S/C Tenerife,
Spain.
390. Long-Term Safety of Abatacept: Integrated Analysis of
Clinical Program Data of up to 7 Years of Treatment. Marc
C. Hochberg 7 , Rene Westhovens 4 , Richard Aranda 2 , Sheila M.
Kelly 2 , Nadar Khan 2 , Keqin Qi 2 , Ramesh Pappu 2 , Ingrid Delaet 2 ,
Allison Luo 2 , Anne Torbeyns 3 , Larry W. Moreland 6 , Roger B.
Cohen 5 , Sheila Gujrathi 2 and Michael E. Weinblatt 1 , 1 Brigham
& Womens Hospital, Boston, MA, 2 Bristol-Myers Squibb,
Princeton, NJ, 3 Bristol-Myers Squibb, Braine-l’Alleud, Belgium,
4
Catholic University of Leuven, Leuven, Belgium, 5 Fox Chase
Cancer Center, Philadelphia, PA, 6 Univ of Pittsburgh Med Ctr,
Pittsburgh, PA, 7 University of Maryland, Baltimore, MD.
391. Long-Term Safety of Rituximab: Follow-Up of the Rheumatoid
Arthritis Clinical Trials and Retreatment Population. Ronald
van Vollenhoven 5 , Paul Emery 2 , Clifton O. Bingham 4 , Edward
C. Keystone 9 , Roy M. Fleischmann 8 , Daniel E. Furst 7 , Katherine
Macey 6 , Marianne Sweetser 1 , Patricia Lehane 6 , Pam Farmer 3
and Simon G. Long 6 , 1 Biogen Idec Inc, 2 Chapel Allerton Hospital,
Leeds, United Kingdom, 3 Genentech Inc, 4 Johns Hopkins
University, Baltimore, MD, 5 Karolinska Institute, Stockholm,
Sweden, 6 Roche Products Ltd, 7 University of California Los
Angeles Medical School, Los Angeles, CA, 8 University of Texas
Southwestern Medical Center, Dallas, TX, 9 University of Toronto,
Toronto, ON, Canada.
392. Low-Dose Glucocorticoid Chronotherapy of Rheumatoid
Arthritis: 12 Week Efficacy and Safety of Modified-Release
(MR) Prednisone. Frank Buttgereit 2 , Daksha P. Mehta 3 , John R.
Kirwan 1 , Jacek Szechinski 7 , Maarten Boers 12 , Rieke Alten 10 , Jerzy
Supronik 8 , István Szombati 9 , Ulrike Römer 4 , Stephan Witte 5 ,
Amy Grahn 6 and Kenneth G. Saag 11 , 1 Bristol Royal Infirmary,
Bristol, United Kingdom, 2 Charite University Med-Berlin,
Berlin, Germany, 3 Ctr Arthritis & Osteoporosis, Elizabethtown,
KY, 4 Horizon Pharma GmbH, Mannheim, Germany, 5 Horizon
Pharma GmbH, Mannheim, Germany, 6 Horizon Pharma, Inc.,
Northbrook, IL, 7 Med. University Dept. of Rheumatology,
Wroclaw, Poland, 8 NZOZ Centrum Medyczne, Bialystok, Poland,
9
OEC, Budapest, Hungary, 10 Schlosspark-Klinik, UnivMed, Berlin,
Germany, 11 University of Alabama-Birmingham, Birmingham, AL,
12
VU University Medical Center, Amsterdam, The Netherlands.
393. Metanalysis on the Effect of TNF-Inhibitors on Lipid Profile.
Claire Immediato Daien 1 , Yohan Duny 3 , Thomas Barnetche 2
and Jacques Morel 1 , 1 Département de Rhumatologie,
Hôpital Lapeyronie, Montpellier, France, 2 Département de
Rhumatologie, Hôpital Pellegrin, Bordeaux, France, 3 Institut
Universitaire de Recherche Clinique, Service de Biostatistiques,
Epidémiologie et Santé Publique, Montpellier, France.
2010 Program Book 173